Table 2 Results of immunohistochemistry staining of all patients with primary testicular lymphoma
Patient no | Classification | GCB/non-GCB | CD20 | CD3 | CD10 | Mum-1 | bcl-6 | Ki-67 |
|---|---|---|---|---|---|---|---|---|
1 | DLBCL | na | + | – | – | + | + | 40% |
2 | DLBCL | non-GCB | + | – | – | + | + | 95% |
3 | DLBCL | GCB | + | – | + | – | + | 80–90% |
4 | DLBCL | non-GCB | + | – | – | + | – | 80–90% |
5 | DLBCL | na | + | – | – | + | + | 75% |
6 | DLBCL | non-GCB | + | – | – | + | + | 90% |
7 | DLBCL | non-GCB | + | – | – | + | + | 85% |
8 | DLBCL | na | + | – | – | + | + | 60% |
9 | DLBCL | non-GCB | + | + | – | + | + | 40% |
10 | DLBCL | non-GCB | + | – | – | + | + | 50% |
11 | DLBCL | non-GCB | + | – | – | + | + | 50–60% |
12 | DLBCL | na | + | – | – | + | na | 50% |
13 | DLBCL | non-GCB | + | – | – | + | – | 80% |
14 | DLBCL | non-GCB | + | – | – | + | + | 70% |
15 | DLBCL | na | + | – | – | + | + | 90% |
16 | DLBCL | non-GCB | + | – | – | + | + | 60–70% |
17 | DLBCL | non-GCB | + | – | – | + | – | 80% |
18 | DLBCL | non-GCB | + | – | – | + | + | 80% |
19 | DLBCL | non-GCB | + | – | – | + | + | 90% |
20 | DLBCL | non-GCB | + | – | – | + | + | 90% |
21 | DLBCL | non-GCB | + | – | – | + | – | 50% |
22 | DLBCL | non-GCB | + | – | – | + | + | 80% |
23 | DLBCL | non-GCB | + | – | – | + | + | 85% |
24 | DLBCL | non-GCB | + | – | – | + | + | 80% |
25 | NK/T lymphoma |  | – | + | – | – | – | 80% 95% 80% 99% |
26 | NK/T lymphoma |  | – | – | – | – | – | 95% |
27 | NK/T lymphoma |  | – | + | na | na | na | 80% |
28 | Burkitt’s lymphoma |  | + | – | + | na | + | 99% |